TaiRx’s New Drug CVM-1118 for Neuroendocrine Tumors Aims for International Licensing Within Six Months

TaiRx has made significant progress in developing a new cancer drug. On the 24th, the company announced that its investigational drug CVM-1118 has achieved its targeted goals in Phase II clinical trials for neuroendocrine tumors (NET) and hepatocellular carcinoma (HCC) this year, marking a major milestone. TaiRx Chairman, Andrew Lin, stated that NET will be the company’s priority focus, with expectations to complete international licensing or joint collaborations within the next six to nine months.